NEW YORK: A COVID-19 vaccine candidate co-developed by the pharmaceutical giant Pfizer and the German biotech firm BioNTech produces a “robust” immune response in healthy adults aged 18–55, according to an interim study of an early phase clinical trial recently published in the journal Nature.
The researchers noted that BNT162b1 is an RNA vaccine that induces an immune response by imitating the mRNA molecule used by the novel SARS-CoV-2 coronavirus to create its infectious proteins.
According to the study the vaccine candidate is delivered intramuscularly and enables human cells to produce proteins part of the SARS-CoV-2 receptor-binding domain, against which the immune system is trained to produce antibodies.
They said that these vaccines are generally considered effective, and have enabled the rapid production of
SARS-CoV-2 vaccines.
SARS-CoV-2 vaccines.
